News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 10 - 20

Beixin Life and Ying Minda Selected as National Key "Little Giant" Enterprises

Recently, the list of the second batch of new key "Little Giant" enterprises, evaluated by the Ministry of Finance and the Ministry of Industry and Information Technology, was announced. Beixin Life and Ying Minda, portfolio companies of Efung Capital, were successfully selected for the list due to their exceptional innovation capabilities and deep technological, joining the ranks of nationally supported key "Little Giant" enterprises.Key "Little Giant" enterprises are selectively chosen from those already recognized as specialized and sophisticated "Little G...

浏览次数：1

查看详情>>

发布时间: 2025 - 10 - 17

Cell Publishes Xunlu Bio's BCMA CAR-T Research for Multiple Sclerosis

On October 16, 2025, Xunlu Bio announced that the internationally top-tier academic journal Cell published online the research results of its self-developed fully human BCMA-targeted CAR-T cell therapy, Equecabtagene Autoleucel, for the treatment of progressive multiple sclerosis (PMS). This study not only demonstrates, for the first time globally, the safety and efficacy of CAR-T cell therapy in treating progressive multiple sclerosis but also represents the first publication in Cell of research results on successful treatment of autoimmune diseases with BCMA-targeted CAR-...

浏览次数：3

查看详情>>

发布时间: 2025 - 10 - 12

First Domestic PDE4 Inhibitor Approved for Marketing

On October 11, the NMPA website showed that Hemei Pharmaceutical's Class 1 new drug "Momisite" was approved for marketing for the treatment of plaque psoriasis (Acceptance Number: CXHS2400033), becoming the first approved domestic PDE4 inhibitor.Momisite (Hemay005) is a phosphodiesterase 4 (PDE4) small molecule inhibitor. According to the Insight database, the drug's clinical trial application was filed as early as 2013, the first clinical trial was initiated in 2016 for the treatment of psoriasis, and the first marketing application was submitted in April 2024 with plaque ps...

浏览次数：7

查看详情>>

发布时间: 2025 - 10 - 11

Yahong Pharma Publishes APL-1702 Phase III Data in Cell Press Med

On October 10, 2025, Yahong Pharma (Stock Code: 688176.SH), a global innovative drug company focused on urogenital tumors and women's health, announced that the results of its international multicenter Phase III clinical trial of APL-1702 for the treatment of high-grade squamous intraepithelial lesion (HSIL) of the cervix have been published online in Med, a journal under Cell Press. Med, founded by Cell Press, is a flagship medical journal launched by Cell Press following Cell and Chem. It is a TOP journal in Journal Citation Reports (JCR) Q1 and a dual first-clas...

浏览次数：3

查看详情>>